Factors associated with change in exacerbation frequency in COPD.

PubWeight™: 1.08‹?› | Rank: Top 10%

🔗 View Article (PMC 3733814)

Published in Respir Res on July 30, 2013

Authors

Gavin C Donaldson1, Hanna Müllerova, Nicholas Locantore, John R Hurst, Peter M A Calverley, Jorgen Vestbo, Antonio Anzueto, Jadwiga A Wedzicha

Author Affiliations

1: Centre for Respiratory Medicine, UCL Medical School, Royal Free Campus, Rowland Hill Street Hampstead, London NW3 2PF, UK. g.donaldson@ucl.ac.uk

Associated clinical trials:

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE) | NCT00292552

Articles citing this

Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med (2015) 1.57

Predictors of early readmission among patients 40 to 64 years of age hospitalized for chronic obstructive pulmonary disease. Ann Am Thorac Soc (2014) 1.36

Explaining the increased health care expenditures associated with gastroesophageal reflux disease among elderly Medicare beneficiaries with chronic obstructive pulmonary disease: a cost-decomposition analysis. Int J Chron Obstruct Pulmon Dis (2014) 0.98

Trends in management and outcomes of COPD patients in primary care, 2000-2009: a retrospective cohort study. NPJ Prim Care Respir Med (2014) 0.94

Reduction of exacerbation frequency in patients with COPD after participation in a comprehensive pulmonary rehabilitation program. Int J Chron Obstruct Pulmon Dis (2014) 0.80

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®). Adv Ther (2015) 0.76

"Frequent exacerbator" is a phenotype of poor prognosis in Japanese patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2016) 0.76

Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization. Int J Chron Obstruct Pulmon Dis (2017) 0.75

Long-term non-invasive ventilation reduces readmissions in COPD patients with two or more episodes of acute hypercapnic respiratory failure. Eur Clin Respir J (2016) 0.75

Stability of the frequent COPD exacerbator in the general population: A Danish nationwide register-based study. NPJ Prim Care Respir Med (2017) 0.75

COPD: it is time to change! Int J Chron Obstruct Pulmon Dis (2015) 0.75

Clinical characteristics of chronic bronchitic, emphysematous and ACOS phenotypes in COPD patients with frequent exacerbations. Int J Chron Obstruct Pulmon Dis (2017) 0.75

Gait deficiencies associated with peripheral artery disease are different than chronic obstructive pulmonary disease. Gait Posture (2017) 0.75

Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med (2017) 0.75

The Challenges of Precision Medicine in COPD. Mol Diagn Ther (2017) 0.75

Articles cited by this

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96

Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55

The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med (2004) 18.60

A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19

Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 10.05

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax (2002) 8.77

Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax (2005) 7.39

Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med (1998) 6.10

Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69

Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 5.49

Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2001) 5.17

Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17

Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 4.87

Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J (2008) 4.53

Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax (2000) 4.45

COPD exacerbations: defining their cause and prevention. Lancet (2007) 3.46

The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J (2004) 2.63

Reproducibility of 6-minute walking test in patients with COPD. Eur Respir J (2010) 2.50

Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest (2006) 2.06

Quantifying the extent of emphysema: factors associated with radiologists' estimations and quantitative indices of emphysema severity using the ECLIPSE cohort. Acad Radiol (2011) 1.88

Exacerbations of chronic obstructive pulmonary disease. Respir Care (2003) 1.80

Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J (2003) 1.78

Lung function decline and outcomes in an elderly population. Thorax (2006) 1.57

A threshold regression model for recurrent exacerbations in chronic obstructive pulmonary disease. J Clin Epidemiol (2010) 1.49

COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respir Res (2011) 1.43

Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis (2010) 1.35

Determinants of poor 6-min walking distance in patients with COPD: the ECLIPSE cohort. Respir Med (2010) 1.30

A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health (2004) 1.17

Negative impacts of unreported COPD exacerbations on health-related quality of life at 1 year. Eur Respir J (2009) 1.12

Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur Respir J (2010) 1.09

The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health (2001) 1.00

Statin use and hospitalization in patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study in Taiwan. Clin Ther (2011) 0.92

Novel uses for anti-platelet agents as anti-inflammatory drugs. Br J Pharmacol (2007) 0.90

Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal (2012) 0.88

Statin pre-treatment is associated with lower platelet activity and favorable outcome in patients with acute non-cardio-embolic ischemic stroke. Crit Care (2011) 0.85

Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets (2011) 0.83

Thrombocytosis in pediatric patients is associated with severe lower respiratory tract inflammation. Arch Med Res (2006) 0.81

Articles by these authors

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86

Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96

Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07

International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57

The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med (2007) 8.06

Noninvasive positive-pressure ventilation for respiratory failure after extubation. N Engl J Med (2004) 7.03

Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med (2013) 6.36

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29

Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17

Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA (2002) 6.00

Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69

Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17

Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 4.87

Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 4.73

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet (2009) 4.40

Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med (2004) 4.24

GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet (2009) 3.93

Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ (2003) 3.87

Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J (2004) 3.77

Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70

Evolution of mechanical ventilation in response to clinical research. Am J Respir Crit Care Med (2007) 3.45

Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44

Ventilator settings as a risk factor for acute respiratory distress syndrome in mechanically ventilated patients. Intensive Care Med (2005) 3.32

The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med (2012) 3.18

Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09

Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA (2008) 3.01

Evolution of mortality over time in patients receiving mechanical ventilation. Am J Respir Crit Care Med (2013) 2.95

Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 2.80

Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2008) 2.66

Risk factors for extubation failure in patients following a successful spontaneous breathing trial. Chest (2006) 2.60

Airway and systemic inflammation and decline in lung function in patients with COPD. Chest (2005) 2.59

Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. Crit Care Med (2011) 2.55

Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52

Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest (2013) 2.42

Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ (2004) 2.39

Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. Crit Care Med (2012) 2.38

Airway pressures, tidal volumes, and mortality in patients with acute respiratory distress syndrome. Crit Care Med (2005) 2.37

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res (2009) 2.31

Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med (2011) 2.30

Effectiveness of innovations in nurse led chronic disease management for patients with chronic obstructive pulmonary disease: systematic review of evidence. BMJ (2005) 2.26

Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20

The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res (2005) 2.18

Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med (2009) 2.17

Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest (2009) 2.16

Characteristics and outcomes of ventilated patients according to time to liberation from mechanical ventilation. Am J Respir Crit Care Med (2011) 2.15

Use and utility of a 24-hour Telephone Support Service for 'high risk' patients with COPD. Prim Care Respir J (2010) 2.14

A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest (2007) 2.14

Impact of sedation and analgesia during noninvasive positive pressure ventilation on outcome: a marginal structural model causal analysis. Intensive Care Med (2015) 2.11

Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. Arch Intern Med (2007) 2.06

Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest (2006) 2.06

Outcomes of patients ventilated with synchronized intermittent mandatory ventilation with pressure support: a comparative propensity score study. Chest (2009) 2.03

The GOLD classification has advanced understanding of COPD. Am J Respir Crit Care Med (2004) 2.00

Macrolide antibiotics for prevention of chronic obstructive pulmonary disease exacerbations: are we there yet? Am J Respir Crit Care Med (2014) 2.00

Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00

Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99

A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98

Outcome of mechanically ventilated patients who require a tracheostomy. Crit Care Med (2005) 1.91

Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.90

Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med (2008) 1.89

Exacerbation rate, health status and mortality in COPD--a review of potential interventions. Int J Chron Obstruct Pulmon Dis (2009) 1.85

Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res (2009) 1.85

Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2003) 1.85

Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest (2006) 1.84

Use of sedatives and neuromuscular blockers in a cohort of patients receiving mechanical ventilation. Chest (2005) 1.82

Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents (2011) 1.80

Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 1.77

Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis (2012) 1.75

Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2005) 1.75

Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med (2004) 1.75

Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2004) 1.73

Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc (2015) 1.72

Use of sedatives, opioids, and neuromuscular blocking agents in patients with acute lung injury and acute respiratory distress syndrome. Crit Care Med (2008) 1.71

Management and outcome of mechanically ventilated neurologic patients. Crit Care Med (2011) 1.71

Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med (2008) 1.68

Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J (2011) 1.68

Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J (2013) 1.66

Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med (2011) 1.64

An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2015) 1.63

Detection and severity grading of COPD exacerbations using the exacerbations of chronic pulmonary disease tool (EXACT). Eur Respir J (2013) 1.62

Non-invasive positive pressure ventilation for treatment of respiratory failure due to severe acute exacerbations of asthma. Cochrane Database Syst Rev (2012) 1.60

Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med (2005) 1.54

Early and small changes in serum creatinine concentrations are associated with mortality in mechanically ventilated patients. Shock (2010) 1.54